Plasma kallikrein, a component of the human kallikrein-related peptidases has been found to have aberrant abundance in multiple cancer types, including GI cancers, which affects the cascade of tumor management, such as trypsin and chymotrypsin-like serine peptidases [31]. This evidence concerns the gene KLK4 and cancer.